FN-1501

Generic Name
FN-1501
Brand Names
Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
Drug Type
Small Molecule
Chemical Formula
C22H25N9O
CAS Number
1429515-59-2
Unique Ingredient Identifier
6MC966B505
Background

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions
Transplanted Organ Rejection
Associated Therapies
-
Clinical Trials
Related News

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

First Posted Date
2019-05-22
Last Posted Date
2024-04-04
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
431
Registration Number
NCT03959241
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Dana Farber Cancer Institute/Brigham & Women's, Boston, Massachusetts, United States

🇺🇸

Ohio State/Arthur G. James Cancer Hospital, Columbus, Ohio, United States

and more 36 locations

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

First Posted Date
2019-05-09
Last Posted Date
2022-10-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT03943147
Locations
🇺🇸

The Regents of The University of California, Los Angeles, California, United States

🇺🇸

NewYork-Presbyterian Queens, Fresh Meadows, New York, United States

🇺🇸

Northwell Health Physician Partners at Great Neck, Great Neck, New York, United States

and more 84 locations

Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis

Phase 4
Terminated
Conditions
Lupus Nephritis
Interventions
Drug: Mycophenolate Mofetil
First Posted Date
2019-04-18
Last Posted Date
2021-02-01
Lead Sponsor
Chulalongkorn University
Target Recruit Count
2
Registration Number
NCT03920059
Locations
🇹🇭

King Chulalongkorn Memorial Hospital, Bangkok, Please Select, Thailand

Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

First Posted Date
2019-04-02
Last Posted Date
2024-12-17
Lead Sponsor
Nilratan Sircar Medical College
Target Recruit Count
100
Registration Number
NCT03899103
Locations
🇮🇳

Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India

Veloxis de Novo Kidney Transplant ECSWD

First Posted Date
2019-02-04
Last Posted Date
2020-05-13
Lead Sponsor
Simon Tremblay, PharmD, PhD
Target Recruit Count
60
Registration Number
NCT03828682
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

🇺🇸

The Christ Hospital, Cincinnati, Ohio, United States

Multicenter Registry of Pediatric Lupus Nephritis in China

First Posted Date
2019-01-03
Last Posted Date
2019-04-05
Lead Sponsor
Xiqiang Dang
Target Recruit Count
1200
Registration Number
NCT03791827
Locations
🇨🇳

The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

First Posted Date
2018-10-19
Last Posted Date
2024-03-05
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
10
Registration Number
NCT03712878
Locations
🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

First Posted Date
2018-10-01
Last Posted Date
2023-10-13
Lead Sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Target Recruit Count
67
Registration Number
NCT03690154
Locations
🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

KUMC Cancer Center, Fairway, Kansas, United States

🇦🇺

Cabrini Malvern Hospital, Malvern, Victoria, Australia

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

First Posted Date
2018-09-28
Last Posted Date
2019-10-28
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
260
Registration Number
NCT03689465
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

🇨🇳

Xiangya Hospital, Central South University, Changsha, Hunan, China

🇨🇳

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

and more 4 locations

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1
Suspended
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia in Remission
Recurrent Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts
Chronic Myelomonocytic Leukemia
Refractory Acute Lymphoblastic Leukemia
Interventions
Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Drug: Cyclophosphamide
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Bone Marrow Transplantation
Drug: Mycophenolate Mofetil
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Fludarabine Phosphate
Drug: Tacrolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection
First Posted Date
2018-09-14
Last Posted Date
2024-05-10
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT03670966
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy